Sputtr.com | Alternative Search Engine

Trastuzumab

Herceptin ® Trastuzumab

Herceptin ® Trastuzumab WARNINGS: Cardiomyopathy Herceptin administration can result in left ventricular dysfunction and congestive heart failure (CHF).

Label - Trastuzumab (Herceptin), Genetech, Inc.

WARNING CARDIOMYOPATHY: HERCEPTIN administration can result in the development of ventricular dysfunction and congestive heart failure. Left ventricular function should be evaluated in all patients prior to and during treatment with HERCEPTIN.

Herceptin (Trastuzumab) Label

HE RC E PTIN@ Tras t uzuma b WARNINGS: CARDf OMYOPATHY HERCEPTIN administration can result in the development of ventricular dysfunction and congestive heart failure.

Trastuzumab — Mechanism of Action and Use in Clinical Practice

The new england journal of medicine n engl j med 357;1 www.nejm.org july 5, 2007 39 Drug Therapy Trastuzumab — Mechanism of Action and Use in Clinical Practice Clifford A. Hudis, M.D.

CIGNA's pharmacy coverage position on trastuzumab (Herceptin)

C IGNA M EDICAL C OVERAGE P OLICY The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans formerly administered by Great-West Healthcare, which is now a part of CIGNA.

Targeting HER2: Beyond Trastuzumab

Newsletter DECEMBER 8 12, 2010 ▫ 33 RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM SAN ANTONIO, TEXAS, USA ▫ WWW.SABCS.ORG I Targeting HER2: Beyond Trastuzumab When trastuzumab (Herceptin) was approved for the treatment of patients with metastatic HER2-positive breast cancer in 1998, many ...

Overview of Trastuzumab's Utility for Gastric Cancer

| Connection 2010 28 Overview of Trastuzumab's Utility for Gastric Cancer Judith Meza-Junco, MD Heather-Jane Au, MD, FRCPC, MPH Michael B. Sawyer, MD, BScPhm, FRCPC Department of Oncology Cross Cancer Institute 11560 University Avenue Edmonton, Alberta, Canada, T6G 1Z2 Abstract Gastric Cancer ...

TA34 Breast cancer - trastuzumab: Guidance

Technology Appraisal No. 34 Guidance on the use of trastuzumab for the treatment of advanced breast cancer. Issue date: March 2002 Review date: April 2005 Ordering Information Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0064.

TA107 Breast cancer (early) - trastuzumab: Guidance

Trastuzumab for the adjuvant treatment of early- stage HER2-positive breast cancer TA107 Breast cancer (early) - trastuzumab: Guidance

CIGNA's pharmacy coverage position on trastuzumab (Herceptin)

C IGNA H EALTH C ARE C OVERAGE P OSITION Subject : Trastuzumab (Herceptin ®) Revised Date..... 12/15/2006 Effective Date ..... 10/15/2005 Coverage Position Number..... 5106 Table of Contents Related Coverage Positions Coverage Position ...